Объективная оценка повреждающего действия глюкокортикоидов (индекс токсичности) у пациентов с системной красной волчанкой

Системная красная волчанка (СКВ) – мультисистемное заболевание, характеризующееся хроническим воспалением и повреждением жизненно важных органов и систем. Несмотря на большие успехи, достигнутые в лечении СКВ, глюкокортикоиды (ГК) остаются одним из основных методов ее терапии. Индекс токсичности ГК является объективным методом оценки нежелательных явлений, связанных с их применением, и в будущих исследованиях может активно использоваться для контроля безопасности различных режимов терапии. Более широкое внедрение данного индекса у пациентов с СКВ позволит оптимизировать подходы к подбору доз ГК, рассматривать более раннее назначение генно-инженерных биологических препаратов, до развития тяжелых необратимых повреждений. 

1. Connelly K, Morand EF, Hoi AY. Asian ethnicity in systemic lupus erythematosus: an Australian perspective. Intern Med J. 2013 Jun;43(6):618-24. doi: 10.1111/imj.12070.

2. Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011 Dec 1;365(22):2110-21. doi: 10.1056/NEJMra1100359.

3. Yen EY, Singh RR. Brief report: lupus-an unrecognized leading cause of death in young females: a population-based study using nationwide death certificates, 2000–2015. Arthritis Rheumatol. 2018 Aug;70(8):1251-5. doi: 10.1002/art.40512. Epub 2018 Jun 27.

4. Danza A, Ruiz-Irastorza G, Khamashta M. Glucocorticoid use and abuse in SLE. Rheumatology (Oxford). 2012 Jul;51(7): 1145-53. doi: 10.1093/rheumatology/ker410. Epub 2012 Jan 23.

5. Lateef A, Petri M. Unmet medical needs in systemic lupus erythematosus. Arthritis Res Ther. 2012;14 Suppl 4(Suppl 4):S4. doi: 10.1186/ar3919.

6. Buttgereit F, Straub RH, Wehling M, Burmester GR. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum. 2004 Nov;50(11):3408-17. doi: 10.1002/art.20583.

7. Ruiz-Irastorza G, Danza A, Khamashta M. Glucocorticoid use and abuse in SLE. Rheumatology (Oxford). 2012 Jul;51(7): 1145-53. doi: 10.1093/rheumatology/ker410.

8. McDonough AK, Curtis JR, Saag KG. The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol. 2008 Mar;20(2):131-7. doi: 10.1097/BOR.0b013e3282f51031.

9. Sarnes E, Crofford L, Watson M, et al. Incidence and US costs of corticosteroidassociated adverse events: a systematic literature review. Clin Ther. 2011 Oct;33(10):1413-32. doi: 10.1016/j.clinthera.2011.09.009.

10. Kirschke E, Goswami D, Southworth D, et al. Glucocorticoid receptor function regulated by coordinated action of the Hsp90 and Hsp70 chaperone cycles. Cell. 2014 Jun 19; 157(7):1685-97. doi: 10.1016/j.cell.2014.04.038.

11. Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum. 2000 Aug;43(8):1801-8. doi: 10.1002/1529-0131(200008)43:83.0.CO;2-O.

12. Thamer M, Hernan MA, Zhang Y, et al. Prednisone, lupus activity, and permanent organ damage. J Rheumatol. 2009 Mar;36(3): 560-4. doi: 10.3899/jrheum.080828.

13. Gladman DD, Urowitz MB, Rahman P, et al. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol. 2003 Sep;30(9):1955-9.

14. Fischer-Betz R, Chehab G, Sander O, et al. Renal outcome in patients with lupus nephritis using a steroid-free regimen of monthly intravenous cyclophosphamide: a prospective observational study. J Rheumatol. 2012 Nov;39(11):2111-7. doi: 10.3899/jrheum.120537.

15. Badsha H, Edwards CJ. Intravenous pulses of methylprednisolone for systemic lupus erythematosus. Semin Arthritis Rheum. 2003 Jun; 32(6):370-7. doi: 10.1053/sarh.2002.50003.

16. Capell HA, Madhok R, Hunter JA, et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis. 2004 Jul; 63(7):797-803. doi: 10.1136/ard.2003.014050.

17. Da Silva JA, Jacobs JW, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2006 Mar;65(3):285-93. doi: 10.1136/ard. 2005.038638.

18. Bel EH, Wenzel SE, Thompson PJ, et al; SIRIUS Investigators. Oral glucocorticoidsparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014 Sep 25;371(13): 1189-97. doi: 10.1056/NEJMoa1403291.

19. Fortunet C, Maillefert JF. Comment on: tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice: reply. Rheumatology (Oxford). 2015 Apr; 54(4):751-2. doi: 10.1093/rheumatology/keu468.

20. McDonough AK, Curtis JR, Saag KG. The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol. 2008 Mar;20(2):131-7. doi: 10.1097/BOR.0b013e3282f51031.

21. Van der Goes MC, Jacobs JW, Boers M, et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis. 2010 Nov;69(11):1913-9. doi: 10.1136/ard.2009.124958.

22. Wassenberg S, Rau R, Steinfeld P, Zeidler H. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2005 Nov;52(11):3371-80. doi: 10.1002/art.21421.

23. Nossent JC. SLICC/ACR Damage Index in Afro-Caribbean patients with systemic lupus erythematosus: changes in and relationship to disease activity, corticosteroid therapy, and prognosis. J Rheumatol. 1998 Apr; 25(4):654-9.

24. Strehl C, Bijlsma JW, de Wit M, et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis. 2016 Jun;75(6):952-7. doi: 10.1136/annrheumdis2015-208916.

25. Santiago T, da Silva JA. Safety of glucocorticoids in rheumatoid arthritis: evidence from recent clinical trials. Neuroimmunomodulation. 2015;22(1-2):57-65. doi: 10.1159/000362726. Epub 2014 Sep 12.

26. Buttgereit F, da Silva JA, Boers M, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis. 2002 Aug; 61(8):718-22. doi: 10.1136/ard.61.8.718.

27. Denburg SD, Carbotte RM, Denburg JA. Psychological aspects of systemic lupus erythematosus: cognitive function, mood, and self-report. J Rheumatol. 1997 May;24(5): 998-1003.

28. Kozora E, Thompson LL, West SG, Kotzin BL. Analysis of cognitive and psychological deficits in systemic lupus erythematosus patients without overt central nervous system disease. Arthritis Rheum. 1996 Dec;39(12): 2035-45. doi: 10.1002/art.1780391213.

29. Treharne GJ, Douglas KM, Iwaszko J, et al. Polypharmacy among people with rheumatoid arthritis: the role of age, disease duration and comorbidity. Musculoskeletal Care. 2007 Dec;5(4):175-90. doi: 10.1002/msc.112.

30. Hoes JN, Jacobs JW, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007 Dec;66(12):1560-7. doi: 10.1136/ard.2007.072157.

31. Miloslavsky EM, Naden RP, Bijlsma JW, et al. Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. Ann Rheum Dis. 2017 Mar;76(3): 543-6. doi: 10.1136/annrheumdis2016-210002.

32. Лебедева ВВ, Муравьев ЮВ, Глухова СИ. Оценка модифицированного комбинированного индекса токсичности глюкокортикоидов при ревматоидном артрите (предварительные данные). Научно-практическая ревматология. 2020;58(1):26-30.